Applying next-generation sequencing to pancreatic cancer treatment

  title={Applying next-generation sequencing to pancreatic cancer treatment},
  author={Elaine R. Mardis},
  journal={Nature Reviews Gastroenterology \&Hepatology},
  • E. Mardis
  • Published 1 August 2012
  • Biology, Medicine
  • Nature Reviews Gastroenterology &Hepatology
Pancreatic cancer is a highly lethal malignancy that presents multiple technical challenges for genomic studies. Next-generation sequencing and its applications have proven successful in the study of other tumour types, unravelling the interplay between DNA and RNA changes that are unique to the tumour. This Review outlines the genomic studies performed to date that have explored the somatic alterations of pancreatic cancer genomes, setting the stage for the introduction of our current… 

The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to Clinic.

  • E. Mardis
  • Biology
    Cold Spring Harbor perspectives in medicine
  • 2018
This review explores this transformation of next-generation sequencing technology and identifies cutting-edge applications of NGS that will result in its additional utility in cancer care.

Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer

Significant challenges will have to be overcome to translate NGS to the bedside of cancer patients, particularly with respect to the requirement for simpler assays, more flexible throughput, shorter turnaround time, and most importantly, easier data analysis and interpretation.

Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset.

Overcoming diagnostic issues in precision treatment of pancreatic cancer

The final challenge, common to all approaches beyond a limited panel of genes, will be the holistic, evidence-based analysis of NGS data for making clinically relevant treatment recommendations.

Bioinformatory‐assisted analysis of next‐generation sequencing data for precision medicine in pancreatic cancer

Software‐analysis of NGS data provides evidence‐based information on effective, ineffective and toxic drugs, potentially forming the basis for precision cancer medicine in PDAC.

Harnessing Massively Parallel Sequencing in Personalized Head and Neck Oncology

Current commercially available NGS platforms are reported briefly on and their clinical applications, ethical considerations, and utilization in personalized patient care are discussed, particularly as this relates to head and neck cancer.

Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing

By using NGS with targeted panels, somatic mutations with therapeutic potential were identified in PAC patients and the combination of clinical and genetic information is useful for decision making and precise selection of targeted medicine.

Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression

It is demonstrated that PDX models derived from advanced or end-stage likely closely approximate the genetics of the disease in the clinic and thus represent a biologically and clinically relevant pre-clinical platform that may enable the development of effective targeted therapies for PDAC.

Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer

A new targeted sequencing by combining single-strand library preparation and target capture (SLHC-seq) is reported, finding that the small mutant fragments are prevalent in early-stage patients, which provides strong evidence for fragment size-based early detection of pancreatic cancer.



Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

The mutations present in advanced cancers can be identified by integrative high-throughput sequencing to enable biomarker-driven clinical trials and, ultimately, treatment and the authors tested this approach by extensively characterizing cancers in several patients and then convening a Sequencing Tumor Board of experts to determine the appropriate treatment.

Pancreatic Carcinogenesis

The elucidation of genetic alterations in combination with the development of high-throughput sensitive techniques should lead to the discovery of effective biomarkers for early detection of this malignancy.

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

It is found that pancreatic cancers contain an average of 63 genetic alterations, the majority of which are point mutations, which defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors.

The Promise of a Personalized Genomic Approach to Pancreatic Cancer and Why Targeted Therapies Have Missed the Mark

  • W. Fisher
  • Medicine
    World Journal of Surgery
  • 2010
The era of personalized genomic medicine has arrived and it is to be hoped that this new approach will result in a significant improvement in the survival curve for patients with PC.

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

It is found that pancreatic cancer acquires rearrangements indicative of telomere dysfunction and abnormal cell-cycle control, namely dysregulated G1-to-S-phase transition with intact G2–M checkpoint, and phylogenetic trees across metastases show organ-specific branches.

Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within thePrimary tumour.

DNA sequencing of a cytogenetically normal acute myeloid leukemia genome

This study establishes whole-genome sequencing as an unbiased method for discovering cancer-initiating mutations in previously unidentified genes that may respond to targeted therapies.

Tumour evolution inferred by single-cell sequencing

It is shown that with flow-sorted nuclei, whole genome amplification and next generation sequencing the authors can accurately quantify genomic copy number within an individual nucleus and indicate that tumours grow by punctuated clonal expansions with few persistent intermediates.

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

The data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression, and two new RNA-editing events that recode the amino acid sequence of SRP9 and COG3 are revealed.

Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Whole-genome sequencing can identify cytogenetically invisible oncogenes in a clinically relevant time frame and change the treatment plan for the patient.